Estee Lauder (NYSE: EL) jumped more than 11% on Friday after the cosmetics company confirmed it had terminated merger discussions with Spanish beauty group Puig Brands, removing what the market had been treating as a significant overhang on the stock and allowing investors to refocus on the company’s existing turnaround strategy.
The deal, which had been announced in March and would have created a luxury beauty entity valued at approximately $40 billion, came apart after both parties concluded their talks could not reach a viable structure.
President and chief executive Stephane de La Faverie framed the outcome as a positive rather than a retreat in a prepared statement. “We are grateful for the conversations we have had with Puig. We are reiterating our confidence in the power of our incredible brands, our talented teams, and our strength as a standalone company. We are more optimistic than ever about our ability to unlock significant long-term value through Beauty Reimagined, and we remain focused on accelerating that progress,” he said.
The market’s reaction tells you exactly how investors had been reading the deal. From the moment merger discussions were confirmed in March, Estee Lauder’s shares had been trading with an integration risk discount built in. Analysts at Jefferies had flagged at the time that the transaction introduced additional complications for the company during a period when it was already executing a demanding internal transformation. Ending the talks removes that complication and returns the narrative to execution against the Beauty Reimagined strategy, which is a story analysts across the Street appear to be increasingly willing to back.
Piper Sandler initiated coverage on Friday with an Overweight rating and a price target of $95, pointing to improving organic growth, Americas market stabilisation, and a potential top-line inflection by fiscal 2027. Rothschild and Co Redburn lifted its target to $70 from $65. The broader analyst consensus sits around $93, with sentiment broadly leaning overweight, suggesting that the deal’s collapse has unlocked rather than closed off the medium-term investment case.
Beauty Reimagined is a multi-year restructuring programme targeting gross savings of $1.0 to $1.2 billion by fiscal 2027. The initiative includes plans to cut up to 3,000 jobs globally and involves significant supply chain streamlining alongside a strategic shift toward premium product launches. The company has separately confirmed that final bids have been received for three of its smaller brands, Too Faced, Smashbox, and Dr. Jart, with a sale decision expected within weeks. Those divestitures would both sharpen the portfolio and provide balance sheet capacity for the restructuring.
The broader fundamental picture remains challenged. Revenue has stagnated over a three-year period with a negative compounded annual growth rate, and EBIT margin of 3.9% sits well below the high-teen levels the company achieved historically. The gross margin of 74% demonstrates that underlying brand economics remain healthy, meaning the profitability gap is a function of cost structure and volume shortfall rather than brand deterioration. That distinction is what makes the turnaround thesis credible.
Puig’s reaction to the news was starkly different. The Spanish group’s shares fell approximately 14% on Friday, reflecting the removal of the premium that investors had been applying to the stock based on the anticipated deal. J.P. Morgan noted the pressure would persist as investor focus shifts back to Puig’s operational performance amid normalising fragrance demand and headwinds in the Middle East and travel retail channels. The stock had already lost significant ground since its April 2024 IPO before this further correction.
For Estee Lauder, the week’s sharp price moves, dropping from around $80 to near $76 in the early part of the week before surging above $91 and closing around $88.53, encapsulate both the volatility the stock has been carrying and the relief the market felt when the merger uncertainty was resolved. The $80 to $82 range now acts as near-term technical support, with $95 representing the primary analyst target for the medium term. Execution against Beauty Reimagined is now the only story that matters.
